News & Events zu Bioceres Crop Solutions Corp (BIOX)BIOXBioceres Crop Solutions Corp

Bioceres Reports Q3 Revenue of $39.4M

Reports Q3 revenue $39.4M, one estimate $54.5M. Mr. Federico Trucco, Bioceres' Chief Executive Officer, commented: "This quarter reflects a period of transition and operational refocusing for the Company. While market conditions in several areas of our business remain challenging, and the effects of the transition in Seeds continue to weigh on reported results, we are increasingly focused on strengthening the fundamentals of the organization and prioritizing disciplined execution across the platform. During the quarter, we continued advancing initiatives aimed at simplifying the organization, improving operational efficiency, strengthening working capital management and improving cash generation and liability management across key operating subsidiaries. In parallel, we are reinforcing governance and internal processes and conducting a strategic review of our continuing operations - including initiatives focused on organizational streamlining and capital allocation optimization - to ensure that capital, management attention, and resources remain aligned with the areas where we believe we can create the greatest long-term value. We recognize the significance of the events surrounding Pro Farm and the uncertainty generated by the ongoing litigation process. While we continue to pursue the appropriate legal course and evaluate constructive alternatives where possible, our priority remains clear: stabilizing the business, preserving the value of our core operations, and positioning the Company for a more resilient and sustainable future."

Bioceres CEO Discusses Financial Challenges and Restructuring Plans

CEO Federico Trucco said, "This communication accompanies the filing of our Form 6-K for the second quarter of fiscal year 2026, covering the six-month period ended 31 December 2025. I want to speak directly to our shareholders about where we stand, what we are focused on, and how we are navigating a period that has been both challenging and clarifying for Bioceres. The financial results for this quarter reflect a difficult external environment - most notably, sustained pressure on Argentine farmer economics driven by commodity price weakness and the well-documented tightening of credit conditions in our core market. These headwinds have affected revenues and working capital across the sector. Against that backdrop, the team has worked hard to protect market share in our key product families - crop protection, crop nutrition, and seed and integrated products - and we have made meaningful progress in realigning our cost structure. Our three business segments generated a consolidated gross margin of 40% year-to-date, consistent with the prior year, which we regard as a demonstration of the underlying resilience of our technology-driven product portfolio. Our priorities for the remainder of the fiscal year are clear: drive operational performance, improve cash generation from the continuing business, and maintain the discipline in working capital management that the current environment demands. The Board has directed Management to develop a comprehensive three-year financial plan for the continuing business - excluding the Pro Farm assets - with a clear focus on profitability improvement and cash flow generation. We will report progress against this plan as it develops. As disclosed fully in our financial statements, a foreclosure auction of the Pro Farm collateral assets took place on 20 January 2026. The bid submitted by the noteholders was $15 million. The carrying value of the net assets subject to foreclosure was approximately $194 million, resulting in an impairment loss of $179 million recognized under IFRS 5 in the current period. We want to be direct with our shareholders: we do not believe the foreclosure process was conducted on commercially reasonable terms, and we are actively pursuing all available legal remedies, including counterclaims. We have reserved all rights in this matter. As of the date of this letter, the foreclosure process has not yet been formally concluded, and we continue to negotiate a transition agreement with the noteholders. The residual debt position following the $15 million consideration remains to be crystallized, and we will update shareholders as that process progresses. Importantly, the Pro Farm assets - primarily activities in the United States and Europe - have been classified as discontinued operations in our financial statements. The continuing Bioceres business, centered on our operations in Argentina and our core technology platforms, remains in operation following the foreclosure. Our financial statements disclose that substantial doubt about the Company's ability to continue as a going concern remains after considering management's plans. We are not minimizing this conclusion - it reflects real uncertainty about our ability to secure additional financing, and we are addressing it with urgency. We are engaged in active discussions with local Argentine financial institutions to refinance current obligations and restore confidence in our business. We are also evaluating asset disposal and new long-term financing options. In February 2026, Rizobacter Argentina S.A. successfully refinanced its Series VIII Class B corporate bonds, extending maturity and demonstrating continued access to the local debt capital market - a constructive step in the right direction. We recognize that these efforts must be matched by a credible and independently validated financial plan. Management is developing plans to address the current capital structure needs for consideration and approval by the Board, to be progressed as we approach the year-end."